Genentech to present new data from neuroscience portfolio at ECTRIMS
Category: #health  By Pankaj Singh  Date: 2019-09-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Genentech to present new data from neuroscience portfolio at ECTRIMS
  • The data from the neuroscience portfolio would be showed at the 35th ECTRIMS between September 11 and 13 in Stockholm.
     
  • The presentations would include entire Phase III outcomes from the SAkuraStar trial investigating satralizumab as a Neuromyelitis Optica Spectrum Disorder treatment.

Genentech, a biotechnology company and a subsidiary of Roche Group, reportedly announced that pivotal data from its neuroscience portfolio would be showcased in the 35th Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) between September 11 and 13 in Stockholm.

The presentations would include entire Phase III outcomes from the SAkuraStar trial investigating satralizumab for the treatment of Neuromyelitis Optica Spectrum Disorder, and latest Multiple Sclerosis research, which offers insights into progression of the disease, it comprises information from Ocrevus ® study that improve the understanding about Neurofilament Light Chain levels as a capable biomarker for forecasting disability results.

Furthermore, longer-term data of over six years to be proposed continue to show constant efficacy and safety outcomes for patients who took Ocrevus treatment previously.

Chief Medical Officer and Global Product Development Head at Genentech, Sandra Horning, M.D., stated that nervous system disorders are very difficult and complex to treat, and the company has grown its commitment towards neuroscience to enhance scientific understanding and care for conditions like Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis.

Horning added that data being shown at ECTRIMS also contains positive Phase III outcomes for satralizumab taken as a monotherapy, a novel approach for the treatment of Neuromyelitis Optica Spectrum Disorder, as well as novel insights utilizing biomarkers to recognize disease progression happening in multiple sclerosis. 

Horning also stated that similar to the company’s approach with Ocrevus regarding Multiple Sclerosis, aiming at B cells as the crucial driver of disease, the company aims to provide satralizumab as an effective Neuromyelitis Optica Spectrum Disorder treatment option.

 

Source credit:  https://www.gene.com/media/press-releases/14805/2019-09-03/genentech-to-present-pivotal-data-for-sa

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Toyota and ENEOS team up to develop hydrogen fuel-cell system in Japan
Toyota and ENEOS team up to develop hydrogen fuel-cell system in Japan
By Pankaj Singh

Japanese automotive giant, Toyota has reportedly tapped Japanese oil & energy corporation, ENEOS, to explore the field of hydrogen-based power to help with the development of a hydrogen fuel-cell system that would power Woven City, Japan’s ...

KPI Global secures 12.5 MW captive solar project from Anupam Rasayan
KPI Global secures 12.5 MW captive solar project from Anupam Rasayan
By Pankaj Singh

Gujarats leading solar power generating company, KPI Global, has recently announced receiving an order for building a 12.5 megawatts solar project under the captive power producer capacity from Surat-headquartered Anupam Rasayan India. It has been r...

Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
By Pankaj Singh

Adverum Biotechnologies, a California based biotech company, has reportedly announced new clinical data from the OPTIC Phase 1 with dose ranging clinical stage trial of gene therapy intravitreal injection namely ADVM-022. The OPTIC trial has enrolle...